Status: Recruiting
Pharmacokinetic-guided Dosing of Emicizumab
The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.
Participants needed: 95
Trial details
Phase: Phase 4Age: 1+Biological sex: MaleType: InterventionalSponsor: Kathelijn FischerUpdated: Mar 20, 2024Locations: 8
Eligibility criteria
Confirmed diagnosis of congenital haemophilia A, with a baseline endogenous FVII... [+5]
Acquired haemophilia A